Vanderbilt University announced a quadrupling of commercialisation earnings to more than $24.5m.

Vanderbilt University has said its commercialisation earnings have quadrupled over a three year period – reaching more than $24.5m for the fiscal year ending 30 June.

Several licensing agreements boosted profits at Vanderbilt’s tech transfer unit, the Vanderbilt Centre for Technology Transfer and Commercialisation (CTTC), over the past year. These include a licence with pharmaceutical firm Bristol-Myers Squibb (BMS) for new drugs tackling Parkinson’s disease, one with BMS peer AstraZeneca for schizophrenic drugs, and a further agreement with motion and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?